- Home
- NBR vs CERT Comparison
NBR vs CERT Comparison
Compare NBR & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBR | CERT |
|---|---|---|
| Founded | 1952 | 2008 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBR | CERT |
|---|---|---|
| Price | $82.42 | $8.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $75.00 | $11.67 |
| AVG Volume (30 Days) | 189.8K | ★ 1.9M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 177.74 | 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $3.65 | $4.18 |
| Revenue Next Year | $4.88 | $5.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $36.66 | $4.45 |
| 52 Week High | $112.90 | $13.88 |
Technical Indicators
Market Signals| Indicator | NBR | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 58.01 |
| Support Level | $75.44 | $8.54 |
| Resistance Level | $86.63 | $8.89 |
| Average True Range (ATR) | 3.10 | 0.32 |
| MACD | -0.95 | 0.06 |
| Stochastic Oscillator | 11.61 | 71.63 |
Price Performance
Historical ComparisonAbout NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.